Abstract
Background: Autoantibodies to exocrine-pancreatic glycoprotein 2 (anti-GP2) are Crohn’s disease (CD) markers. However, CD-specific antibodies have also been found in celiac-disease (CeD) patients, in which type 1 diabetes-specific autoantibodies against endocrine pancreatic targets can be present. We investigated whether anti-GP2 are also present in CeD, a disease like CD which is also characterised by intestinal mucosal inflammation with barrier impairment.
Methods: Antibodies against GP2, tissue transglutaminase (tTG), deamidated gliadin (dGD), glutamic decarboxylase (GAD), and islet antigen-2 (IA2) were tested in sera from 73 CD patients, 90 blood donors (BD), and 79 (58 de novo) CeD patients (2 consecutive sera were available from 40 patients).
Results: IgA and/or IgG anti-GP2 were found in 15/79 (19.0%) CeD patients on at least one occasion, in 25/73 (34.2%) CD patients, and in 4/90 (4.4%) BD (CeD vs. CD, p=0.042; BD vs. CeD and CD, p<0.001, respectively). Amongst the 58 de novo CeD patients, anti-GP2 IgA and/or IgG were present in 11 (19.0%). Anti-GP2 IgA was significantly less prevalent in CeD compared with CD (p=0.004). Anti-GP2 IgA and IgG in CD patients demonstrated a significantly higher median level compared to patients with CeD (p<0.001, p=0.008, respectively). IgA anti-GP2 levels correlated significantly with IgA anti-tTG and anti-dGD levels in CeD Spearman’s coefficient of rank correlation (ρ)=0.42, confidence interval (CI): 0.26–0.56, p<0.001; ρ=0.54, CI 0.39–0.65, p<0.001, respectively.
Conclusions: The presence of anti-GP2 in CeD patients supports the notion that loss of tolerance to GP2 can probably be a manifestation of an autoinflammatory process in this intestinal disorder.
Acknowledgments
We thank Doreen Dillaerts for expert technical assistance.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Financial support: None declared.
Employment or leadership: Dirk Roggenbuck is a shareholder of GA Generic Assays GmbH and Medipan GmbH. The remaining authors declare that they have no competing financial interests.
Honorarium: None declared.
Competing interests: The funding organisation(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Roggenbuck D, Hausdorf G, Martinez-Gamboa L, Reinhold D, Buttner T, Jungblut PR, et al. Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn’s disease. Gut 2009;58:1620–8.10.1136/gut.2008.162495Search in Google Scholar PubMed
2. Komorowski L, Teegen B, Probst C, Aulinger-Stocker K, Sina C, Fellermann K, et al. Autoantibodies against exocrine pancreas in Crohn’s disease are directed against two antigens: the glycoproteins CUZD1 and GP2. J Crohns Colitis 2013;7:780–90.10.1016/j.crohns.2012.10.011Search in Google Scholar PubMed
3. Laass MW, Roggenbuck D, Conrad K. Diagnosis and classification of Crohn’s disease. Autoimmun Rev 2014;13:467–71.10.1016/j.autrev.2014.01.029Search in Google Scholar PubMed
4. Hase K, Kawano K, Nochi T, Pontes GS, Fukuda S, Ebisawa M, et al. Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response. Nature 2009;462:226–30.10.1038/nature08529Search in Google Scholar PubMed
5. Terahara K, Yoshida M, Igarashi O, Nochi T, Pontes GS, Hase K, et al. Comprehensive gene expression profiling of Peyer’s patch M cells, villous M-like cells, and intestinal epithelial cells. J Immunol 2008;180:7840–6.10.4049/jimmunol.180.12.7840Search in Google Scholar PubMed
6. Roggenbuck D, Reinhold D, Werner L, Schierack P, Bogdanos DP, Conrad K. Glycoprotein 2 antibodies in Crohn’s disease. Adv Clin Chem 2013;60:187–208.10.1016/B978-0-12-407681-5.00006-4Search in Google Scholar PubMed
7. Werner L, Paclik D, Fritz C, Reinhold D, Roggenbuck D, Sturm A. Identification of pancreatic Glycoprotein 2 as an endogenous immunomodulator of innate and adaptive immune responses. J Immunol 2012;189:2774–83.10.4049/jimmunol.1103190Search in Google Scholar PubMed
8. Holzl MA, Hofer J, Kovarik JJ, Roggenbuck D, Reinhold D, Goihl A, et al. The zymogen granule protein 2 (GP2) binds to scavenger receptor expressed on endothelial cells I (SREC-I). Cell Immunol 2011;267:88–93.10.1016/j.cellimm.2010.12.001Search in Google Scholar PubMed PubMed Central
9. Roggenbuck D, Reinhold D, Wex T, Goihl A, von Arnim U, Malfertheiner P, et al. Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn’s disease. Clin Chim Acta 2011;412:718–24.10.1016/j.cca.2010.12.029Search in Google Scholar PubMed
10. Bogdanos DP, Rigopoulou EI, Smyk DS, Roggenbuck D, Reinhold D, Forbes A, et al. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn’s disease specific-pancreatic autoantibodies. Autoimmun Rev 2011;11:143–8.10.1016/j.autrev.2011.09.004Search in Google Scholar PubMed
11. Op de Beeck K, Vermeire S, Rutgeerts P, Bossuyt X. Antibodies to GP2, the major zymogen granule membrane glycoprotein, in inflammatory bowel diseases. Gut 2012;61:162–4.Search in Google Scholar
12. Bogdanos DP, Roggenbuck D, Reinhold D, Wex T, Pavlidis P, von Arnim U, et al. Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn’s disease. BMC Gastroenterol 2012;12:102.10.1186/1471-230X-12-102Search in Google Scholar
13. Pavlidis P, Romanidou O, Roggenbuck D, Mytilinaiou M, Al-Sulttan F, Liaskos C, et al. Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn’s disease. Clin Dev Immunol 2012;2012:640835.10.1155/2012/640835Search in Google Scholar
14. Somma V, Ababneh H, Ababneh A, Gatti S, Romagnoli V, Bendia E, et al. The novel Crohn’s disease marker anti-GP2 antibody is associated with ileocolonic location of disease. Gastroenterol Res Pract 2013;2013:683824.10.1155/2013/683824Search in Google Scholar
15. Rieder F, Franke A, Dirmeier A, Lopez R, Lang S, Roggenbuck D, et al. Mo1247 serologic anti-GP2 antibodies are associated with strictures and need for surgical resection in Crohn’s disease. Gastroenterology 2013;144:S617.10.1016/S0016-5085(13)62280-5Search in Google Scholar
16. Roggenbuck D, Humbel RL, Reinhold D, Bogdanos DP, Conrad K, Laass MW. Glycoprotein 2 antibodies in inflammatory bowel disease – no association with disease phenotype? J Pediatr Gastroenterol Nutr 2012;56:e5.10.1097/MPG.0b013e318275fa77Search in Google Scholar
17. Bonaci-Nikolic B, Spuran M, Andrejevic S, Nikolic M. Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, in patients with gluten-sensitive enteropathy: a possible serological trap. Clin Chim Acta 2012;413:822–3.10.1016/j.cca.2012.01.005Search in Google Scholar
18. Ludvigsson JF, Leffler DA, Bai JC, Biagi F, Fasano A, Green PH, et al. The Oslo definitions for coeliac disease and related terms. Gut 2013:62:43–52.10.1136/gutjnl-2011-301346Search in Google Scholar
19. Soderholm JD, Olaison G, Lindberg E, Hannestad U, Vindels A, Tysk C, et al. Different intestinal permeability patterns in relatives and spouses of patients with Crohn’s disease: an inherited defect in mucosal defence? Gut 1999;44:96–100.10.1136/gut.44.1.96Search in Google Scholar
20. Bjarnason I. Intestinal permeability. Gut 1994;35:S18–22.10.1136/gut.35.1_Suppl.S18Search in Google Scholar
21. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369:1627–40.10.1016/S0140-6736(07)60750-8Search in Google Scholar
22. Rieder F, Lawrance IC, Leite A, Sans M. Predictors of fibrostenotic Crohn’s disease. Inflamm Bowel Dis 2011;17:2000–7.10.1002/ibd.21627Search in Google Scholar PubMed
23. Bardella MT, Elli L, De MS, Floriani I, Torri V, Piodi L. Autoimmune disorders in patients affected by celiac sprue and inflammatory bowel disease. Ann Med 2009;41:139–43.10.1080/07853890802378817Search in Google Scholar PubMed
24. Basso D, Zambon CF, Plebani M. Inflammatory bowel diseases: from pathogenesis to laboratory testing. Clin Chem Lab Med 2014;52:471–81.10.1515/cclm-2013-0588Search in Google Scholar PubMed
25. Vermeersch P, Geboes K, Marien G, Hoffman I, Hiele M, Bossuyt X. Diagnostic performance of IgG anti-deamidated gliadin peptide antibody assays is comparable to IgA anti-tTG in celiac disease. Clin Chim Acta 2010;411:931–5.10.1016/j.cca.2010.02.060Search in Google Scholar PubMed
26. Vermeersch P, Geboes K, Marien G, Hoffman I, Hiele M, Bossuyt X. Serological diagnosis of celiac disease: comparative analysis of different strategies. Clin Chim Acta 2012;413:1761–7.10.1016/j.cca.2012.06.024Search in Google Scholar PubMed
27. Conrad K, Roggenbuck D, Ittenson A, Reinhold D, Buettner T, Laass MW. A new dot immunoassay for simultaneous detection of celiac specific antibodies and IgA-deficiency. Clin Chem Lab Med 2011;50:337–43.Search in Google Scholar
28. Zöphel K, Wunderlich G, Kotzerke J, von Landenberg P, Roggenbuck D. M22 based (manual) ELISA for TSH-receptor antibody (TRAb) measurement is more sensitive than 2nd generation TRAb assays. Clin Chim Acta 2009;403:266.10.1016/j.cca.2009.01.022Search in Google Scholar PubMed
29. Sollid LM. Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol 2002;2:647–55.10.1038/nri885Search in Google Scholar PubMed
30. Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 2001;49:402–8.10.1136/gut.49.3.402Search in Google Scholar PubMed PubMed Central
31. de Kort S, Keszthelyi D, Masclee AA. Leaky gut and diabetes mellitus: what is the link? Obes Rev 2011;12:449–58.10.1111/j.1467-789X.2010.00845.xSearch in Google Scholar PubMed
32. Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem 2006;52:171–81.10.1373/clinchem.2005.058560Search in Google Scholar PubMed
33. Bonifacio E, Lampasona V, Genovese S, Ferrari M, Bosi E. Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies. J Immunol 1995;155:5419–26.10.4049/jimmunol.155.11.5419Search in Google Scholar
34. Baekkeskov S, Kanaani J, Jaume JC, Kash S. Does GAD have a unique role in triggering IDDM? J Autoimmun 2000;15:279–86.10.1006/jaut.2000.0443Search in Google Scholar PubMed
35. Conrad K, Schmechta H, Klafki A, Lobeck G, Uhlig HH, Gerdi S, et al. Serological differentiation of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2002;14:129–35.10.1097/00042737-200202000-00006Search in Google Scholar PubMed
36. Michielan A, Basso D, Martinato M, Pathak S, Banerjee A, Oliva L, et al. Increased antibody response to microbial antigens in patients with Crohn’s disease and their unaffected first-degree relatives. Dig Liver Dis 2013;45:894–8.10.1016/j.dld.2013.01.017Search in Google Scholar PubMed
37. Roggenbuck D, Reinhold D, Schierack P, Bogdanos DP, Conrad K, Laass MW. Crohn’s disease specific pancreatic antibodies: clinical and pathophysiological challenges. Clin Chem Lab Med 2014;52:483–94.10.1515/cclm-2013-0801Search in Google Scholar PubMed
38. Pavlidis P, Forbes A, Bogdanos DP. Antibodies to glycoprotein 2 (GP2) in patients with inflammatory bowel diseases from UK. Clin Chim Acta 2011;412:1163–4.10.1016/j.cca.2011.02.005Search in Google Scholar PubMed
39. Roggenbuck D, Bogdanos D, Conrad K. Loss of tolerance to one or two major targets in Crohn’s disease or just cross-reactivity? J Crohns Colitis 2013;7:e273–4.10.1016/j.crohns.2012.12.013Search in Google Scholar PubMed
40. Schierack P, Rödiger S, Kolenda R, Hiemann R, Berger E, Grzymailo K, et al. Species-specific and pathotype-specific binding of bacteria to zymogen granule membrane glycoprotein 2 (GP2). Gut [Epub ahead of print 2014 Jul 29]. doi:10.1136/gutjnl-2014-307854 (in press).10.1136/gutjnl-2014-307854Search in Google Scholar PubMed
41. Colombel JF, Watson AJ, Neurath MF. The 10 remaining mysteries of inflammatory bowel disease. Gut 2008;57:429–33.10.1136/gut.2007.122192Search in Google Scholar PubMed
42. Gullberg E, Soderholm JD. Peyer’s patches and M cells as potential sites of the inflammatory onset in Crohn’s disease. Ann N Y Acad Sci 2006;1072:218–32.10.1196/annals.1326.028Search in Google Scholar PubMed
43. Cornes JS. Peyer’s patches in the human gut. Proc R Soc Med 1965;58:716.10.1177/003591576505800930Search in Google Scholar PubMed PubMed Central
44. Gross S, Bakker SF, van Bodegraven AA, van Hoogstraten IM, Gelderman KA. Increased IgA glycoprotein-2 specific antibody titres in refractory CD. J Gastrointestin Liver Dis 2014;23:1–7.10.15403/jgld.2014.1121.232.sg1Search in Google Scholar PubMed
45. Werner L, Sturm A, Roggenbuck D, Yahav L, Zion T, Meirowithz E, et al. Antibodies against glycoprotein 2 are novel markers of intestinal inflammation in patients with an ileal pouch. J Crohns Colitis 2013;7:e522–32.10.1016/j.crohns.2013.03.009Search in Google Scholar PubMed
46. Werner L, Roggenbuck D, Dotan I. Reply to Dr. Pavlidis et al.’s letter. J Crohns Colitis 2013;7:e604–5.10.1016/j.crohns.2013.06.017Search in Google Scholar PubMed
47. Roggenbuck D, Reinhold D, Wex T, von Arnim U, Malfertheiner P, Sturm A, et al. Authors’ response: antibodies to GP2, the major zymogen granule membrane glycoprotein, are specific for Crohn’s disease and may reflect treatment response. Gut 2012;61:164–5.10.1136/gut.2010.237214Search in Google Scholar
48. Kovacs M, Lakatos PL, Papp M, Jacobsen S, Nemes E, Polgar M, et al. Pancreatic autoantibodies and autoantibodies against goblet cells in pediatric patients with inflammatory bowel disease (IBD). J Pediatr Gastroenterol Nutr 2012;55:429–35.10.1097/MPG.0b013e318256b516Search in Google Scholar PubMed
©2015 by De Gruyter
